Rituximab as treatment for minimal residual disease in hairy cell leukaemia
- 2 November 2004
- journal article
- clinical trial
- Published by Wiley in European Journal of Haematology
- Vol. 73 (6) , 412-417
Abstract
Abstract: Purine analogues have dramatically improved the outcome of patients affected by hairy cell leukemia (HCL), although complete eradication of disease was achieved in few cases. The purpose of this study was to evaluate the role of Rituximab in eradicating minimal residual disease (MRD) in HCL patients after a pre‐treatment with 2‐chloro‐deoxy‐adenosine (2‐CdA). Ten patients received four cycles of Rituximab after administration of Cladribrine. Before starting anti‐CD20 antibody, two patients were in complete remission, six in partial remission and two showed no significant response to Cladribrine. All cases resulted IgH‐positive. Median time from the last 2‐CdA infusion was 5.7 months. Eight of 10 patients [four in partial remission (PR), two in complete remission (CR) and two unresponsive after 2‐CdA] were evaluable for response. Two months after the end of anti‐CD20 therapy, all evaluated patients presented a complete haematological remission. Moreover, Rituximab increased percentage of molecular remission up to 100% 1 yr after the end of treatment. Interestingly, in all cases but one, including those persistently polymerase chain reaction (PCR)‐positive, semi‐quantitative molecular analyses showed MRD levels lower than those found before Rituximab administration. Toxicity was very mild. The present results not only confirm the therapeutic effect of Rituximab, but also show its relevance in eradicating MRD in HCL.Keywords
This publication has 28 references indexed in Scilit:
- Rituximab in relapsed or refractory hairy cell leukemiaBlood, 2003
- Immunobiological treatments of hairy-cell leukaemiaBest Practice & Research Clinical Haematology, 2003
- The mechanisms of action of rituximab in the elimination of tumor cellsSeminars in Oncology, 2003
- Rituximab: a useful drug for a repeatedly relapsed hairy cell leukemia patientAnnals of Hematology, 2002
- Different clinical value of minimal residual disease after autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemiaBlood, 2002
- Higher Levels of Surface CD20 Expression on Circulating Lymphocytes Compared With Bone Marrow and Lymph Nodes in B-Cell Chronic Lymphocytic LeukemiaAmerican Journal of Clinical Pathology, 2001
- Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell LeukemiaNew England Journal of Medicine, 2001
- The significance of minimal residual disease in hairy cell leukaemia treated with deoxycoformycin: a long‐term follow‐up studyBritish Journal of Haematology, 1997
- Lasting Remissions in Hairy-Cell Leukemia Induced by a Single Infusion of 2-ChlorodeoxyadenosineNew England Journal of Medicine, 1990
- Interferon is effective in hairy‐cell leukaemiaBritish Journal of Haematology, 1985